SCHEMBL12469760

SCHEMBL12469760

CC(C)COc1ccccc1C1CC(=O)Nc2cc3c(cc21)OC(F)(F)O3

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.78
TP53 P04637 6/20 0.78
TSHR P16473 10/20 0.61
LMNA P02545 9/20 0.61
NPSR1 Q6W5P4 5/20 0.61
MAPK1 P28482 4/20 0.59
ALOX15 P16050 2/20 0.59
RAB9A P51151 1/20 0.59
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
ALDH1A1 P00352 1/20 0.56
HPGD P15428 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
MAPT P10636 1/20 0.52
POLB P06746 2/20 0.51
GAA P10253 3/20 0.49
HSD17B10 Q99714 1/20 0.49
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12698410 0.89 TSHR (0.77) SMN1; SMN2TP53TSHRLMNANPSR1
SCHEMBL12469836 0.88 SMN1; SMN2 (1.00) SMN1; SMN2TP53TSHRLMNANPSR1
SCHEMBL12469941 0.87 LMNA (0.78) SMN1; SMN2TP53TSHRLMNANPSR1
SCHEMBL12469830 0.86 LMNA (0.71) SMN1; SMN2TP53TSHRLMNANPSR1
SCHEMBL12470138 0.85 TSHR (0.76) SMN1; SMN2TP53TSHRLMNANPSR1
SCHEMBL12698408 0.82 SMN1; SMN2 (0.72) SMN1; SMN2TP53TSHRLMNANPSR1
SCHEMBL18648918 0.81 TSHR (0.74) SMN1; SMN2TP53TSHRLMNANPSR1
SCHEMBL18648916 0.79 SMN1; SMN2 (0.68) SMN1; SMN2TP53TSHRLMNANPSR1
SCHEMBL12469820 0.78 SMN1; SMN2 (0.67) SMN1; SMN2TP53TSHRLMNANPSR1
SCHEMBL12469684 0.76 SMN1; SMN2 (1.00) SMN1; SMN2TP53TSHRLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10392398-B2 Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERSITY (US) 2019-08-27 US disclosed
US-20180051033-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2018-02-22 US disclosed
US-20180051033-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2018-02-22 US disclosed
US-9815845-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERSITY (US) 2017-11-14 US disclosed
US-9815845-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERSITY (US) 2017-11-14 US disclosed
US-9802948-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERISTY (US) 2017-10-31 US disclosed
US-9802948-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERISTY (US) 2017-10-31 US disclosed
US-20170107227-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2017-04-20 US disclosed
US-20170107227-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2017-04-20 US disclosed
US-9597325-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERSITY (US) 2017-03-21 US disclosed
US-9597325-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERSITY (US) 2017-03-21 US disclosed
US-20170044175-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2017-02-16 US disclosed
US-20170044175-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2017-02-16 US disclosed
WO-2012050985-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2012-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170107227-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS GTF2F1, HDGF, GTF3C5 SMN1; SMN2 4673/4885TP53 33/4885TSHR 3901/4885
US-20170044175-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS GTF2F1, HDGF, GTF3C5 SMN1; SMN2 4673/4885TP53 33/4885TSHR 3901/4885
US-20180051033-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS GTF2F1, HDGF, GTF3C5 SMN1; SMN2 4673/4885TP53 33/4885TSHR 3901/4885
US-10392398-B2 Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics GTF2F1, HDGF, GTF3C5 SMN1; SMN2 4673/4885TP53 33/4885TSHR 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.